GLAUKOS CORP.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 907
- Market Cap
- $7.4B
- Website
- http://www.glaukos.com
Clinical Trials
63
Trial Phases
5 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Conditions
- Glaucoma
- Interventions
- Drug: Gen 2 Travoprost Intracameral ImplantOther: Placebo eye dropsProcedure: Sham Procedure
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 610
- Registration Number
- NCT07075718
- Locations
- 🇺🇸
Glaukos Investigative Site, Oklahoma City, Oklahoma, United States
🇺🇸Glaukos Clinical Site, El Paso, Texas, United States
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
- Conditions
- Glaucoma, Open-angleOcular Hypertension (OHT)Phacoemulsification Cataract Surgery
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 132
- Registration Number
- NCT06848946
- Locations
- 🇺🇸
Glaukos Investigator Site, Kenosha, Wisconsin, United States
Performance of the Travoprost Intraocular Implant
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 210
- Registration Number
- NCT06582732
- Locations
- 🇦🇲
Glaukos Clinical Study Site, Yerevan, Armenia
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT06152861
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Newport Beach, California, United States
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
- Conditions
- Glaucoma, Open-Angle
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT06066645
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Colorado Springs, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
iVeena Submits IND Application for Novel Non-Atropine Eye Drop to Treat Pediatric Myopia
iVeena Delivery Systems has submitted an Investigational New Drug application to the FDA for IVMED-85, a first-in-class eye drop targeting pediatric myopia through lysyl oxidase activation.
Pipeline Analysis Reveals 20+ Therapies in Development for Open-Angle Glaucoma Treatment
DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials.